NCT06137417 is a clinical trial of PET/CT in Peritoneal Metastases, sponsored by Aya Khaled Mahmoud.

Who is sponsoring NCT06137417?

NCT06137417 is sponsored by Aya Khaled Mahmoud.

What drugs are being tested in NCT06137417?

Interventions in NCT06137417: PET/CT.

What condition does NCT06137417 study?

NCT06137417 studies Peritoneal Metastases.

Is NCT06137417 still recruiting?

NCT06137417 is currently status unknown. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT06137417

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Role of PET/CT in Peritoneal Deposits Assessment

Status unknown Last updated 18 November 2023

What this trial tests

trial testing PET/CT in Peritoneal Metastases in 50 participants. Status unknown.

Timeline

1 January 2024

Primary endpoint
1 January 2026

15 March 2026

Quick facts

Lead sponsor	Aya Khaled Mahmoud
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 January 2024
Primary completion	1 January 2026
Estimated completion	15 March 2026

Drugs / interventions tested

PET/CT

Conditions studied

Peritoneal Metastases — all drugs for Peritoneal Metastases →

Sponsor

Aya Khaled Mahmoud

Who can join

18 and older, any sex, with Peritoneal Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

• Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions and will do PET/CT for assessment of peritoneal deposits

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PET/CT

Trials testing the same drug.

NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07523997 — Imaging of Endometriosis With Total-body PET-CT (PET-Endo) · not yet recruiting
NCT06914427 — PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique · NA · not yet recruiting
NCT06636175 — 64Cu-LLP2A for Imaging Hematologic Malignancies · EARLY_PHASE1 · recruiting
NCT06479187 — PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer · Phase 4 · active not recruiting

Other recruiting trials for Peritoneal Metastases

Currently open trials in the same condition.

NCT06903325 — A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence · recruiting
NCT06367270 — The Application of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Surface Malignancies · Phase 2 · recruiting
NCT05722275 — Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics · recruiting
NCT03413254 — Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases · Phase 3 · active not recruiting
NCT03280511 — Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06137417 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aya Khaled Mahmoud
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06137417.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing